Shop

Author at Microdose

Madison Roberts

Madison Roberts is a nomadic journalist exploring the intersections of cutting-edge science, tech and human well-being. She immerses in diverse cultures, uncovering compelling stories in biotech, neuropsychiatry, neuroscience, mental health, psychedelics and longevity research. Her writing blends scientific rigor with human narratives, resonating across readers. Passionate about the brain's intricacies and psychedelics' healing potential, she's a thought-provoking, empathetic storyteller. Between interviews and breakthroughs, Madison cherishes tranquil moments exploring new landscapes.

Breaking News, Health & Wellness, Industry, Press Releases, Psychedelic Groundbreakers, Psychedelic Titans, Science

15 Jul 2025

Enveric’s EB-003 Shows Promise in PTSD Model, Offering a New Direction in Trauma Treatment

Enveric Biosciences announced that its lead compound, EB-003, significantly reduced trauma-related fear behaviors in a preclinical PTSD model—highlighting its potential as a fast-acting, non-hallucinogenic treatment for a condition with few...

By Madison Roberts

Breaking News, Industry, Science

1 Jul 2025

Enveric’s EB-003 Shows Dual Mechanism Promise, Paving a New Path in Neuropsychiatric Drug Innovation

Enveric Biosciences (NASDAQ: ENVB) is quietly making a case to lead the next generation of neuropsychiatric drug innovation. On June 24, the company announced new data that could significantly broaden...

By Madison Roberts

Breaking News, Press Releases, Science

3 Jun 2025

Enveric’s Patent Win Targets New Frontiers in Sleep Medicine

With U.S. Patent No. 12,187,679 now granted, Enveric Biosciences has secured more than intellectual property—it’s staked a claim on the future of neurotherapeutics. The Cambridge-based biotech firm announced this week...

By Madison Roberts

Industry

20 May 2025

Enveric Biosciences Stakes Its Claim in Neurodegeneration Market

Enveric Biosciences is quietly making a bold move into the neurodegenerative disease space with a new class of molecules targeting the critical BDNF/TrKB pathway. While still in early stages, this...

By Madison Roberts

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

8 May 2025

A Psychedelic Turning Point: How a Landmark Review Re‑frames Psilocybin’s Role in Treating Addiction

Groundbreaking analysis of every modern clinical study on psilocybin for substance‑use disorders shows the psychedelic, when delivered with structured therapy, can dramatically cut drinking and smoking rates and sustain long‑term...

By Madison Roberts

Healing, Health & Wellness

28 Apr 2025

The New Epidemic: How Trauma and Digital Exposure Are Shaping a Teen Mental Health Crisis

The mental health of today's teens is under unprecedented strain, with trauma and digital saturation driving record levels of anxiety, depression, and suicidal ideation. In “Impact of Trauma and Digital...

By Madison Roberts

Industry

8 Apr 2025

No More Silence: The Opioid Epidemics Alarming Impact on Women

Women are facing a silent crisis in the opioid epidemic, with overdose deaths among women aged 30–64 skyrocketing by 260% since 1999. Beyond the statistics lie the stories of mothers,...

By Madison Roberts

Industry, Psychedelic Titans, Science

31 Mar 2025

The Future of Psychedelics: Why Next-Generation Molecules Will Win

The psychedelic industry is undergoing a major transformation. With new, non-hallucinogenic compounds on the rise, companies like Enveric Biosciences, Delix Therapeutics, and Gilgamesh Pharmaceuticals are leading the way in developing...

By Madison Roberts

Breaking News, Finance, Press Releases

25 Feb 2025

Enveric Biosciences’ Patent For Non-Hallucinogenic Psychedelic Compounds

Enveric Biosciences (NASDAQ: ENVB) has received its first U.S. patent for the EVM401 Series, a collection of non-hallucinogenic compounds derived from mescaline. These novel therapeutics target multiple neurological receptors associated...

By Madison Roberts

Follow us on social

Latest News

PTSD, Policy Shifts, and the Rise of Neuroplastogens: What Enveric’s Latest Data Signals for the Field

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

You Might Also Like

19 Jan 2026

Starting 2026: Why Neuroplastogens Are Quietly Redefining the Psychedelic Medicine Narrative

An industry wide look at how neuroplastogens are reshaping psychedelic medicine in 2026, with insights on Delix, AbbVie’s Gilgamesh acquisition, Enveric, and the shift toward nonhallucinogenic brain therapeutics....

By Madison Roberts

17 Dec 2025

Psychedelics in 2025: A Year of Proof, Pullback, and a Clearer Path Forward

If 2024 was the year the psychedelic field learned how hard “approval ready” really is, 2025 was the year it began behaving accordingly. The past twelve months were less about...

By Madison Roberts

26 Nov 2025

Delix Therapeutics Reports Strong Phase Ib Results

Delix Therapeutics recently announced compelling data from a Phase Ib trial of DLX-001 (zalsupindole), a non-hallucinogenic neuroplastogen. According to the company’s release, DLX-001 produced robust biomarker signals (quantitative EEG and...

By Madison Roberts

19 Nov 2025

Childhood Trauma’s Role in Men’s Substance Use Disorders

Childhood trauma leaves a deeper imprint on men’s lives than most realize—and for many, it becomes the hidden engine driving substance use disorders. Research shows that emotional abuse, physical violence,...

By Madison Roberts

19 Nov 2025

Human-Centered AI in Healthcare

Artificial intelligence is redefining modern healthcare, offering powerful tools that enhance diagnosis, expedite drug discovery, and enable truly personalized treatment. As health systems struggle with rising costs, aging populations, and...

By Madison Roberts

16 Oct 2025

Enveric Biosciences Doubles Down on IP Strength as Psychedelic Biotech Sector Heats Up

As Big Pharma makes billion-dollar bets in the evolving landscape of neuropsychiatric therapeutics, Enveric Biosciences (NASDAQ: ENVB) is carving out a formidable position — not by chasing headlines, but by...

By Madison Roberts
WordPress Ads
No Result
View All Result

© 2026 JNews - Premium WordPress news & magazine theme by Jegtheme.